Update on Lupus Erythematosus and Dermatomyositis

The presentation focuses on recent developments regarding Lupus Erythematosus and Dermatomyositis, which are both autoimmune diseases. It underscores that lupus can manifest in various skin forms, including chronic cutaneous lupus and discoid lupus, and discusses the new 2019 ACR criteria for diagnosing systemic lupus erythematosus (SLE), which now requires a positive ANA test. This has significant implications for patient treatment and classification, potentially excluding certain patients from accessing new therapies. The speaker discusses the spectrum of lupus, highlighting how some patients exhibit only skin disease, while others may develop systemic issues. New treatments for cutaneous lupus include hydroxychloroquine and an emphasis on lifestyle changes like sun protection and smoking cessation. Dermatomyositis poses additional challenges due to misdiagnosis as lupus, underscored by the necessity for better diagnostic criteria. The update reviews treatments such as immunosuppressives, IVIG, and the potential for emerging therapies targeting specific pathways in lupus and dermatomyositis. The need for ongoing patient follow-up for potential systemic disease in cutaneous patients and the impact of herbal supplements and vaccines on disease exacerbation is also mentioned, aiming to improve patient outcomes through better understanding and treatment.